Wedbush reiterates Outperform on Xenon Pharmaceuticals, $55 PT
Wedbush maintained an Outperform rating on Xenon Pharmaceuticals and set a $55.00 price target, implying 4.1% downside versus the Sep 17 close of $57.35.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.